セベラマー、塩酸セベラマー
WordNet
- a complex consisting of an organic base in association with hydrogen chloride
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/05 22:23:21」(JST)
[Wiki en表示]
Sevelamer
|
| Systematic (IUPAC) name |
poly(allylamine-
co-N,N'-diallyl-1,3-diamino-2-hydroxypropane) |
| Clinical data |
| Trade names |
Renagel, Renvela |
| AHFS/Drugs.com |
monograph |
| MedlinePlus |
a601248 |
|
Pregnancy
category
|
|
|
Legal status
|
- Schedule 4 (Australia), Rx only (US)
|
|
Routes of
administration
|
oral |
| Pharmacokinetic data |
| Bioavailability |
nil |
| Metabolism |
nil |
| Half-life |
n/a |
| Excretion |
faecal 100% |
| Identifiers |
|
CAS Registry Number
|
52757-95-6 Y |
|
ATC code
|
V03AE02 |
| PubChem |
CID 3085017 |
| DrugBank |
DB00658 N |
| ChemSpider |
2341997 N |
| UNII |
941N5DUU5C N |
| KEGG |
D08512 Y |
| ChEMBL |
CHEMBL1201492 N |
| Chemical data |
| Formula |
[(C3H7N)a+b.(C9H17N2O)c]m
where a+b:c = 9:1 |
|
Molecular mass
|
variable |
| N (what is this?) (verify) |
Sevelamer (rINN) (// or //) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is currently marketed by Sanofi under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Contents
- 1 Chemistry and pharmacology
- 2 Clinical use
- 2.1 Indications
- 2.2 Contraindications
- 2.3 Adverse effects
- 2.4 Other effects
- 3 References
- 4 External links
Chemistry and pharmacology
Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin.[1] The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.
Clinical use
Indications
Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease on hemodialysis.
Contraindications
Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.
Adverse effects
Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.
Other effects
Sevelamer can significantly reduce serum uric acid.[2] This reduction has no known detrimental effect and several beneficial effects, including reducing hyperuricemia, uric acid nephrolithiasis, and gout.
References
- ^ (1) Rosenbaum, D. P.; Mandeville, W. H.; Pitruzzello, M.; Goldberg, D. I. Nephrology Dialysis Transplantation Effect of RenaGel A , a Non-Absorbable , Cross-Linked , Polymeric Phosphate Binder , on Urinary Phosphorus Excretion in Rats. 1997, 961–964.
- ^ Garg JP, Chasan-Taber S, Blair A et al. (January 2005). "Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial". Arthritis and rheumatism 52 (1): 290–5. doi:10.1002/art.20781. PMID 15641045.
External links
- Sevelamer - medlineplus.org
- Renagel - genzyme.com
- Renvela - genzyme.com
|
Drugs for treatment of hyperkalemia and hyperphosphatemia (V03AE)
|
|
| Potassium binders |
|
|
| Phosphate binders |
- Aluminium hydroxide
- Calcium acetate
- Calcium acetate/magnesium carbonate
- Calcium carbonate
- Colestilan
- Lanthanum carbonate
- Sevelamer
- Sucroferric oxyhydroxide
|
|
|
Index of the urinary system
|
|
| Description |
- Anatomy
- Physiology
- Development
- Cells
|
|
| Disease |
- Electrolyte and acid-base
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
- Urine tests
- Blood tests
|
|
| Treatment |
- Procedures
- Drugs
- Intravenous fluids
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Subtherapeutic serum quetiapine concentrations after absorption inhibition by binding resins: a case report.
- Hoge RH1, Arbouw ME, Radstake SD, van Berlo-van de Laar IR.
- Journal of clinical pharmacy and therapeutics.J Clin Pharm Ther.2015 Jun;40(3):355-7. doi: 10.1111/jcpt.12265. Epub 2015 Mar 25.
- WHAT IS KNOWN AND OBJECTIVE: Polystyrene sulfonate and sevelamer are binding resins that are used in the treatment of, respectively, hyperkalemia and hyperphosphatemia. It is unknown whether these resins interact with the antipsychotic quetiapine.CASE SUMMARY: We report on a woman with unexplainable
- PMID 25808008
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
- Floege J1, Covic AC2, Ketteler M3, Mann JF4, Rastogi A5, Spinowitz B6, Chong EM7, Gaillard S7, Lisk LJ7, Sprague SM8; Sucroferric Oxyhydroxide Study Group.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.Nephrol Dial Transplant.2015 Jun;30(6):1037-46. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16.
- BACKGROUND: Hyperphosphatemia necessitates the use of phosphate binders in most dialysis patients. Long-term efficacy and tolerability of the iron-based phosphate binder, sucroferric oxyhydroxide (previously known as PA21), was compared with that of sevelamer carbonate (sevelamer) in an open-label P
- PMID 25691681
- Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo 1.
- Bobeck EA1, Hellestad EM1, Sand JM1, Piccione ML1, Bishop JW1, Helvig C2, Petkovich M3, Cook ME4.
- Poultry science.Poult Sci.2015 Jun 1;94(6):1128-37. doi: 10.3382/ps/pev085. Epub 2015 Mar 29.
- Hyperimmunized hens are an effective means of generating large quantities of antigen specific egg antibodies that have use as oral supplements. In this study, we attempted to create a peptide specific antibody that produced outcomes similar to those of the human pharmaceutical, sevelamer HCl, used i
- PMID 25825784
Japanese Journal
- 塩酸セベラマーの長期投与が血液透析患者の動脈硬化, 脂質代謝に与える影響について
- 二次性副甲状腺機能亢進症を合併した透析患者の副甲状腺摘出術において術中intact PTHモニタリングを行った1例
- Effect of switching from sevelamer hydrochloride to lanthanum carbonate on metabolic acidosis in dialysis patients
Related Links
- Renagel - Tablets (as hydrochloride) 400 mg - Tablets (as hydrochloride) 800 mg Renvela - Tablets (as carbonate) 800 mg - Suspension, oral (as carbonate) 0.8 g per packet - Suspension, oral (as carbonate) 2.4 g per packet
- Sevelamer HCl | C6H13Cl2NO | CID 159247 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. NIH ...
★リンクテーブル★
[★]
- 英
- sevelamer
- 商
- レナジェル、フォスブロック、セベラマー塩酸塩
- 化
- 塩酸セベラマー sevelamer hydrochloride
- 関
- 高リン血症
[★]
- 関
- sevelamer hydrochloride
[★]
塩酸塩、ハイドロクロライド